-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Down 17.8% in December
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Down 17.8% in December
Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) was the target of a large decrease in short interest during the month of December. As of December 15th, there was short interest totalling 194,300 shares, a decrease of 17.8% from the November 30th total of 236,400 shares. Based on an average daily trading volume, of 39,000 shares, the short-interest ratio is presently 5.0 days. Approximately 5.4% of the shares of the company are short sold.
Insider Activity at Greenwich LifeSciences
In other news, CEO Snehal Patel bought 2,000 shares of Greenwich LifeSciences stock in a transaction on Friday, December 9th. The stock was purchased at an average cost of $13.11 per share, with a total value of $26,220.00. Following the purchase, the chief executive officer now directly owns 2,724,886 shares of the company's stock, valued at approximately $35,723,255.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders acquired a total of 13,500 shares of company stock valued at $145,510 in the last quarter. Insiders own 52.14% of the company's stock.
Get Greenwich LifeSciences alerts:Institutional Trading of Greenwich LifeSciences
A number of institutional investors have recently made changes to their positions in GLSI. Vanguard Group Inc. lifted its stake in shares of Greenwich LifeSciences by 150.2% in the 1st quarter. Vanguard Group Inc. now owns 375,200 shares of the company's stock worth $7,362,000 after acquiring an additional 225,213 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of Greenwich LifeSciences in the 2nd quarter worth approximately $891,000. Millennium Management LLC acquired a new stake in shares of Greenwich LifeSciences in the 2nd quarter worth approximately $765,000. Occudo Quantitative Strategies LP acquired a new stake in shares of Greenwich LifeSciences in the 2nd quarter worth approximately $199,000. Finally, Pura Vida Investments LLC acquired a new stake in shares of Greenwich LifeSciences in the 3rd quarter worth approximately $179,000. 6.18% of the stock is owned by institutional investors and hedge funds.
Greenwich LifeSciences Trading Down 4.0 %
Greenwich LifeSciences stock traded down $0.61 during midday trading on Tuesday, reaching $14.59. 43,565 shares of the stock traded hands, compared to its average volume of 40,585. The firm has a fifty day moving average price of $12.18 and a two-hundred day moving average price of $10.26. Greenwich LifeSciences has a fifty-two week low of $6.82 and a fifty-two week high of $26.27.Greenwich LifeSciences (NASDAQ:GLSI – Get Rating) last posted its earnings results on Monday, November 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.01. Sell-side analysts expect that Greenwich LifeSciences will post -0.57 earnings per share for the current year.
Greenwich LifeSciences Company Profile
(Get Rating)
Greenwich LifeSciences, Inc, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
Further Reading
- Get a free copy of the StockNews.com research report on Greenwich LifeSciences (GLSI)
- Can Investors Cash In On PayPal?
- These 3 Tech Stocks Are in for a Happier New Year
- Tyson Foods: Growth and Momentum at a Reasonable Price
- Can Duke Energy Stock Continue Powering Higher?
- Ready for a Recession? Here's One Defensive Stock You Can't Miss
Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
格林威治生命科学公司(纳斯达克:GLSI-GET评级)是空头股数12月份大幅下跌的目标。截至12月15日,空头股数共有19.43万股,比11月30日的23.64万股减少了17.8%。以日均成交量3.9万股计算,目前短息比为5.0天。该公司约5.4%的股份被卖空。
格林威治生命科学公司的内幕活动
其他消息方面,首席执行官斯内哈尔·帕特尔在12月9日(星期五)的一笔交易中购买了2,000股Greenwich LifeSciences股票。这只股票的平均价格为每股13.11美元,总价值为26,220.00美元。收购完成后,这位首席执行官现在直接拥有2,724,886股公司股票,价值约35,723,255.46美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可在这个环节。上个季度,内部人士总共收购了13,500股公司股票,价值145,510美元。内部人士持有该公司52.14%的股份。
到达格林威治生命科学警报:格林威治生命科学的机构交易
一些机构投资者最近改变了他们在GLSI的头寸。先锋集团在第一季度增持了150.2%的Greenwich LifeSciences股票。先锋集团在此期间增持了225,213股,目前持有375,200股该公司股票,价值7,362,000美元。复兴科技有限责任公司在第二季度收购了格林威治生命科学公司价值约891,000美元的新股。千禧管理公司在第二季度收购了格林威治生命科学公司价值约76.5万美元的新股。Occudo Quantity Strategy LP在第二季度收购了格林威治生命科学公司价值约199,000美元的新股。最后,Pura Vida Investments LLC在第三季度收购了价值约179,000美元的格林威治生命科学公司的新股份。6.18%的股票由机构投资者和对冲基金持有。
格林威治生命科学公司股价下跌4.0%
周二午盘交易中,Greenwich LifeSciences的股价下跌0.61美元,至14.59美元。该股有43,565股易手,而其平均成交量为40,585股。该公司的50日移动平均价为12.18美元,200日移动平均价为10.26美元。Greenwich LifeSciences的股价为6.82美元,为52周低点,52周高点为26.27美元。格林威治生命科学公司(纳斯达克代码:GET Rating)最近一次公布财报是在11月14日(星期一)。该公司公布本季度每股收益(EPS)为0.18美元,比分析师普遍预期的0.19美元高出0.01美元。卖方分析师预计,Greenwich LifeSciences本年度每股收益将达到0.57美元。
格林威治生命科学公司简介
(获取评级)
格林威治生命科学公司是一家临床阶段的生物制药公司,专注于为乳腺癌和其他表达HER2/neu的癌症开发新型癌症免疫疗法。它的主要候选产品是GP2,这是一种免疫疗法,已经完成了IIb期临床试验,以防止以前接受过手术的患者的乳腺癌复发。
进一步阅读
- 免费获取StockNews.com关于格林威治生命科学(GLSI)的研究报告
- 投资者能从PayPal中获利吗?
- 这三只科技股将迎来一个更快乐的新年
- 泰森食品:合理价格的增长和动力
- 杜克能源类股能否继续走高?
- 准备好迎接经济衰退了吗?这里有一只你不能错过预期的防御性股票
接受《格林威治生活科学日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Greenwich LifeSciences和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧